Search | Clinical Trials Finder

Conditions: Sickle Cell Anemia, Severe Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria (PNH), Pure Red Cell Aplasia
Interventions: Campath, Chemo and/or TBI Allo SCT; Drug
Lead sponsor: David Rizzieri, MD; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2009
U.S. locations: 2
States / cities: Orlando, Florida • Durham, North Carolina

Conditions: Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD), Hereditary Anemias, Inflammatory Conditions, Systemic Juvenile Idiopathic Arthritis (sJIA), Juvenile Rheumatoid Arthritis (JRA)
Interventions: Hydroxyurea, Alemtuzumab, Fludarabine, Melphalan, Thiotepa; Drug
Lead sponsor: Paul Szabolcs; Other
Eligibility: 2 Months to 55 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hemolytic Disease of the Fetus and Newborn
Interventions: M281; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 8
States / cities: San Francisco, California • New York, New York • Cincinnati, Ohio + 5 more

Conditions: Sickle Cell Disease
Interventions: 25 mg/day zinc, 40 mg/day zinc; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 15 Years to 40 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 6
States / cities: Oakland, California • Durham, North Carolina • Cincinnati, Ohio + 2 more

Conditions: Sickle Cell Disease, Sickle Cell Trait
Interventions: Healthy volunteers without SCT, Healthy volunteers with SCT; Other
Lead sponsor: UConn Health; Other
Eligibility: 50 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Sickle Cell Disease
Interventions: Patient Navigator, Recruitment into Specialty Care; Behavioral
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 15 Years and older
Enrollment: 353 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Sickle Cell Trait
Interventions: Biologic Specimen Collection; Other
Lead sponsor: National Alliance for Sickle Cell Centers; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 8
States / cities: Birmingham, Alabama • Wilmington, Delaware • Indianapolis, Indiana + 5 more

Conditions: Anemia, Sickle Cell, Complex and Transfusion-dependent Hemoglobinopathies, Thalassemia, Diamond-Blackfan Anemia, Bone Marrow Failure Syndromes, Alpha-Thalassemia, Beta-Thalassemia
Interventions: Enriched Hematopoetic Stem Cell Infusion; Biological
Lead sponsor: Talaris Therapeutics Inc.; Industry
Eligibility: Up to 45 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 3
States / cities: Chicago, Illinois • Louisville, Kentucky • Durham, North Carolina

Conditions: Sickling Disorder Due to Hemoglobin S
Interventions: 131I-apamistmab, Sirolimus, Campath, Total Body Irradiation, Exchange Transfusion, Planar gamma imaging; Drug · Radiation · Procedure
Lead sponsor: Columbia University; Other
Eligibility: 12 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: New York, New York

Conditions: Sickle Cell Disease, Thalassemia, Severe Congenital Neutropenia, Diamond-Blackfan Anemia, Shwachman-Diamond Syndrome
Interventions: Busulfan, Fludarabine, ATG, TLI, Busulfan, Cyclophosphamide, ATG, GCSF, Campath, Fludarabine, Cyclophosphamide, Total Body Irradiation, Stem cell infusion; Drug · Radiation · Procedure
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 50 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2020
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Healthy, Sickle Cell Anemia
Interventions: Placebo, PF-07209326; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 16 Years to 70 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 16
States / cities: New Haven, Connecticut • Washington D.C., District of Columbia • Fort Myers, Florida + 6 more

Conditions: Sickle Cell Disease, Thalassemia
Interventions: CordIn; Biological
Lead sponsor: Gamida Cell ltd; Industry
Eligibility: 2 Years to 25 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Oakland, California • Washington D.C., District of Columbia

Conditions: Sickle Cell Disease, Chronic Pain
Interventions: Music Therapy; Other
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Anemia, Sickle Cell
Interventions: Monthly blood transfusion regimen, Usual care; Procedure · Behavioral
Lead sponsor: UCSF Benioff Children's Hospital Oakland; Other
Eligibility: 21 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2010
U.S. locations: 14
States / cities: Oakland, California • Washington D.C., District of Columbia • Hollywood, Florida + 10 more

Conditions: Glucosephosphate Dehydrogenase Deficiency, Favism
Interventions: Primaquine; Drug
Lead sponsor: Walter Reed Army Institute of Research (WRAIR); Federal
Eligibility: 18 Years to 60 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Neuropathic Pain, Sickle Cell Disease
Interventions: Eight Percent Topical Capsaicin; Drug
Lead sponsor: Children's Hospital of Michigan; Other
Eligibility: 14 Years to 21 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Alpha-Thalassemia, Alpha Thalassemia Major, Alpha Thalassemia Minor
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: Not listed
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2037
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Leukemia, Acute Lymphocytic (ALL), Leukemia, Myeloid, Acute(AML), Leukemia, Myeloid, Chronic(CML), Juvenile Myelomonocytic Leukemia(JMML), Hemoglobinuria, Paroxysmal Nocturnal (PNH), Lymphoma, Non-Hodgkin (NHL), Myelodysplastic Syndrome (MDS)
Interventions: Miltenyi Biotec CliniMACS, Stem Cell Transplantation, TBI, systemic chemotherapy and antibodies as follows:; Device · Procedure · Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 2 Years to 21 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Iron Overload
Interventions: deferiprone; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Sickle Cell Disease
Interventions: tAN device; Device
Lead sponsor: Emory University; Other
Eligibility: 7 Years to 18 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Sickle Cell Disease, HEMOGLOBIN SS, Hemoglobin S Beta-0 Thalassemia, Inflammation, Quality of Life
Interventions: Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA), Placebo Capsules; Dietary Supplement · Other
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 10 Years to 19 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania

Conditions: Beta-Thalassemia
Interventions: LentiGlobin BB305 Drug Product; Genetic
Lead sponsor: Genetix Biotherapeutics Inc.; Industry
Eligibility: 0 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 3
States / cities: Oakland, California • Chicago, Illinois • Philadelphia, Pennsylvania

Conditions: Sickle Cell Disease
Interventions: Verum Acupressure (using AcuWand), Sham Acupressure (using AcuWand); Device
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Irvine, California • Indianapolis, Indiana

Conditions: Anemia, Sickle Cell
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 3,640 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 13
States / cities: Oakland, California • San Francisco, California • Boston, Massachusetts + 6 more

Search by objective public record fields.

Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes

Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT

A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Pregnant Women at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn (HDFN)

Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial

Bone Loss, Physical Function and Frailty in Older Women With Sickle Cell Trait Sickle Cell Trait

Enhancing Use of Hydroxyurea In Sickle Cell Disease Using Patient Navigators

Achieving Understanding of the Natural History of Sickle Cell Trait (AUNT)

Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies

131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD)

Stem Cell Transplant for Hemoglobinopathy

Dose Escalation Study of PF-07209326 in Healthy Participants and Participants With Sickle Cell Disease

Allogeneic SCT of CordIn™, in Patients With Hemoglobinopathies

MUSic Therapy to Improve Quality Of Life in Sickle Cell Disease (MUSIQOLS)

Examining Cognitive Function and Brain Abnormalities in Adults With Sickle Cell Disease - Pilot Intervention Study

A Test to Predict the Hemolytic Potential of Drugs in G6PD Deficiency

Sickle Cell Pain: Intervention With Capsaicin Exposure

International Registry of Patients With Alpha Thalassemia

Haploidentical Stem Cell Transplantation for Patients With Hematologic Malignancies

Compassionate Use of Deferiprone for Patients With Thalassemia and Iron-Induced Heart Disease

Trans-auricular Nerve Stimulation as an Innovative Approach to the Treatment of Pain in Pediatric Patients Suffering From Sickle Cell Disease

A Randomized Trial of LOVAZA in Pediatric Sickle Cell Disease (SCD)

A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia, Who do Not Have a β0/β0 Genotype

Acupressure in Patients With Sickle Cell Disease

Establishing a Repository of Blood and DNA Samples From People With Sickle Cell Disease (Comprehensive Sickle Cell Centers Collaborative Genotype-Phenotype Database and Sample Repository)